Slide 1
Image is not available

Our mission is to develop a radically new approach for the treatment of severe, chronic autoimmune diseases.

Technology Platform

The Imcyse technology platform represents the next generation of therapeutic biologics. Modified peptides - ImotopesTM - specifically block the immune responses that cause immune-mediated diseases. ImotopeTM technology is designed to intervene and stop an autoimmune response at a time when damaged tissue can still regenerate or be used in combination with current treatment options to provide a potentially curative treatment approach to severe chronic diseases.

Imcyse’s innovative technology discovery is based on a specific thioredox motif (a few amino-acids in length) that combine target antigenic natural HLA-Class II peptidic epitopes to form ImotopesTM. The Company’s platform selects well known T cell epitopes and use them to design and produce indication specific ImotopesTM.

An injection with ImotopesTM generates ImotopeTM-specific cytolytic CD4 T cells (cCD4) capable of inducing apoptosis of antigen-presenting cells (APC) that activate pathogenic lymphocytes responsible for tissue damage of the diseased organ. ImotopeTM-induced cytolytic T cells specifically eliminate antigen-presenting cells and autoantigen specific lymphocytes, thereby avoiding autoimmune attacks without affecting other functions of the immune system.

Imcyse’s approach to immune tolerance could also be considered as “immune-deletion” of the specific immune cells involved in the immune reaction rather than “immune-suppression”; this is quite unique and distinctively different from what most others in the field are trying to accomplish, e.g. induction of T(regs).

Multiple proof-of-concept (PoC) studies have been conducted in autoimmune disease indications, including but not limited to: type 1 diabetes multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), rheumatoid arthritis (RA), allergy, celiac disease, graft vs. host rejection, myasthenia gravis as well as in the prevention of immunogenicity in gene therapy using AAV-Vectors. 




Avenue Pré-Aily 14
4031 Liège (Angleur)

Phone : +32 (0)4 325 1100